^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LEU001

    i
    Other names: LEU001, LEU-001, LEU 001, 4ab T1E28z positive T-cells, Intra-tumoral T4 immunotherapy, panErbB-specific CAR T cells
    Associations

    News

    Trials
    Company:
    King's College London, Leucid Bio
    Drug class:
    Pan HER-targeted CAR-T immunotherapy
    Associations

    News

    Trials
    over1year
    Phase I Trial: T4 Immunotherapy of Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, King's College London | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • LEU001
    over2years
    Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. (PubMed, J Immunother Cancer)
    These data demonstrate the safe intratumoral administration of T4 immunotherapy in advanced HNSCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IL4 (Interleukin 4)
    |
    Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec) • LEU001